

# Florence F Wagner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1907378/publications.pdf>

Version: 2024-02-01

18  
papers

1,063  
citations

567281

15  
h-index

839539

18  
g-index

21  
all docs

21  
docs citations

21  
times ranked

2256  
citing authors

#	ARTICLE	IF	CITATIONS
1	Multigram Preparation of BRD4780 Enantiomers and Assignment of Absolute Stereochemistry. Journal of Organic Chemistry, 2021, 86, 4281-4289.	3.2	2
2	GSK3 <sup>1</sup> , not GSK3 <sup>2</sup> , drives hippocampal NMDAR-dependent LTD via tau-mediated spine anchoring. EMBO Journal, 2021, 40, e105513.	7.8	75
3	Roles of glycogen synthase kinase 3 alpha and calcineurin in regulating the ability of sperm to fertilize eggs. FASEB Journal, 2020, 34, 1247-1269.	0.5	9
4	Exploiting the Therapeutic Interaction of WNT Pathway Activation and Asparaginase for Colorectal Cancer Therapy. Cancer Discovery, 2020, 10, 1690-1705.	9.4	38
5	Selective inhibition of glycogen synthase kinase 3 <sup>1</sup> corrects pathophysiology in a mouse model of fragile X syndrome. Science Translational Medicine, 2020, 12, .	12.4	42
6	Small Molecule Targets TMED9 and Promotes Lysosomal Degradation to Reverse Proteinopathy. Cell, 2019, 178, 521-535.e23.	28.9	124
7	Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias. Cancer Cell, 2019, 35, 664-676.e7.	16.8	70
8	Glycogen synthase kinase 3- <sup>1</sup> inhibition induces lymphangiogenesis through <sup>1</sup> -catenin-dependent and mTOR-independent pathways. PLoS ONE, 2019, 14, e0213831.	2.5	9
9	Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. Science Translational Medicine, 2018, 10, .	12.4	69
10	Kinetic and structural insights into the binding of histone deacetylase 1 and 2 (HDAC1, 2) inhibitors. Bioorganic and Medicinal Chemistry, 2016, 24, 4008-4015.	3.0	51
11	Inhibitors of Glycogen Synthase Kinase 3 with Exquisite Kinome-Wide Selectivity and Their Functional Effects. ACS Chemical Biology, 2016, 11, 1952-1963.	3.4	55
12	Selective HDAC Inhibition for the Disruption of Latent HIV-1 Infection. PLoS ONE, 2014, 9, e102684.	2.5	65
13	Small Molecule Inhibitors of Zinc-dependent Histone Deacetylases. Neurotherapeutics, 2013, 10, 589-604.	4.4	81
14	Therapeutic potential of isoform selective HDAC inhibitors for the treatment of schizophrenia. Future Medicinal Chemistry, 2013, 5, 1491-1508.	2.3	34
15	Class I HDAC imaging using [ <sup>3</sup> H]CI-994 autoradiography. Epigenetics, 2013, 8, 756-764.	2.7	28
16	A Selective HDAC 1/2 Inhibitor Modulates Chromatin and Gene Expression in Brain and Alters Mouse Behavior in Two Mood-Related Tests. PLoS ONE, 2013, 8, e71323.	2.5	118
17	Inhibition of Histone Deacetylase 3 Protects Beta Cells from Cytokine-Induced Apoptosis. Chemistry and Biology, 2012, 19, 669-673.	6.0	85
18	AKT Kinase Activity Is Required for Lithium to Modulate Mood-Related Behaviors in Mice. Neuropsychopharmacology, 2011, 36, 1397-1411.	5.4	98